Apr2024
Ariana Pharma announces important Artificial Intelligence (AI) collaboration in precision oncology to accelerate a first-in class antibody blocking lipid metabolism for the treatment of advanced cancer
Artificial Intelligence and organoid data to accelerate the development of a first-in-class antibody in precision oncology. Paris, France and Cambridge, MA, USA, 16th April, 2024, Ariana Pharma, a leading Artificial Intelligence drug development company, announced today that it has entered a €3 million consortium sponsored by the Eurostars 3 program, led by ONA Therapeutics SL, […]
Nov2023
ESMO 2023: Advances in the fight against cancer through artificial intelligence.
The collaboration between Ariana Pharma, Omicure, and the Léon Bérard Center has led to a breakthrough in identifying survival biomarkers across various cancer types using eXplainable Artificial Intelligence. In a study, presented at ESMO 2023 [Identification of biomarkers of survival across multiple cancer types using eXplainable Artificial Intelligence], KEM®, a proprietary Ariana Pharma technology, was […]
May2023
Ariana Pharma continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological […]
Jun2022
Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Mar2019
Colon Cancer and combination therapy: Ariana to present data at AACR 2019 using its AI technology and PDX mouse model simulated clinical trial
Ariana to present data at AACR 2019 on using its KEM® Artificial Intelligence technology and PDX mouse models to simulate patient stratification in clinical trials and Identify companion biomarkers for combination therapy Ariana Pharma, a leading digital health Company focused on developing advanced therapeutic decision support systems, will present its latest results on combination therapy […]
Oct2018
Ariana Pharma helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial
Ariana Pharma helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial. Ariana®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. Ariana’s KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, shows that patients receiving the VAL401 treatment […]
Sep2018
Recombio and Ariana Pharma Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy
Ariana has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Ariana Pharma (Paris, France and […]
Jan2018
Ariana’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients
Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, […]
Dec2017
Ariana®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients
London, Paris and Boston, 12 December 2017: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 […]
Jun2017
WIN 2017 (Paris | Jun 26-27)
Meet the Ariana team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.